ClinicalTrials.Veeva

Menu

A Study of Galcanezumab in Healthy Participants.

Lilly logo

Lilly

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Biological: Galcanezumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT02836613
16203
I5Q-MC-CGAQ (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to evaluate how much galcanezumab gets into the body after it is given as an injection just under the skin by two different devices. This study will measure how much galcanezumab reaches the blood stream and will test how it affects calcitonin-gene related peptide (CGRP) in blood. Information about any side effects that may occur will be collected. The study will last about 20 weeks for each participant. Screening is required within 45 days prior to the start of the study.

Enrollment

160 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Overtly healthy as determined by medical history and physical examination
  • Have a body mass index (BMI) between 19.0 and 35.0 kilogram per meter square (kg/m²)
  • Have clinical laboratory test results within normal reference range for the investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator

Exclusion criteria

  • Have previously completed or withdrawn from this study or any other study investigating galcanezumab, and have previously received galcanezumab
  • Have allergies to either humanized monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone
  • Intend to use over-the-counter or prescription medication within 7 days prior to dosing and during the study (especially systemic glucocorticoids, immunomodulatory drugs, drugs with propensity for dermal reactions, drugs with known hepatic toxicity, etc). Stable doses of hormone replacement therapy (HRT) are allowed for inclusion at the discretion of the investigator
  • Have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

160 participants in 2 patient groups

Galcanezumab Reference
Active Comparator group
Description:
Single dose of 240 milligrams (mg) galcanezumab (LY2951742) administered subcutaneously (SC) by manual prefilled syringe (PFS).
Treatment:
Biological: Galcanezumab
Galcanezumab Test
Experimental group
Description:
Single dose of 240 mg galcanezumab (LY2951742) administered SC by autoinjector.
Treatment:
Biological: Galcanezumab

Trial documents
2

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems